Lv5
1500 积分 2021-03-29 加入
Biomarker analysis of a randomized, placebo-controlled, double-blind, multicenter phase II trial of intravenous RO5137382/GC33 at 1600 mg Q2W in previously treated patients with unresectable advanced or metastatic hepatocellular carcinoma (HCC) (NCT01507168)
1个月前
已关闭
Boswellia Carteri: A Potential Antibacterial Agent Against common Bacterial Pathogens: In Vitro Study
1个月前
已关闭
Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR-T and TCR-T Cell Therapies: An Industry Perspective
2个月前
已完结
Chimeric antigen receptor T cell therapy: 25years in the making
2个月前
已完结
FDA Experience on CAR T Cell Pharmacokinetics/Pharmacodynamics and Model-Based Assessments
2个月前
已完结
Preclinical development and a case report of a nanobody-based CLDN18.2 CAR-T IMC002 with reduced on-target off-tumor toxicity
5个月前
已完结
Adult Stem Cell Treatment for Rheumatoid Arthritis
5个月前
已完结
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial
5个月前
已完结
The changing landscape of cancer cell therapies: clinical trials and real-world data
5个月前
已完结
Optimizing CAR T cell therapy for solid tumours: a clinical perspective
5个月前
已完结
皖公网安备34019202002308
